🚀 VC round data is live in beta, check it out!
Citius Pharmaceuticals Valuation Multiples
Discover revenue and EBITDA valuation multiples for Citius Pharmaceuticals and similar public comparables like DexTech Medical, Quantum BioPharma, Exact Therapeutics, Biofrontera and more.
Citius Pharmaceuticals Overview
About Citius Pharmaceuticals
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.
Founded
2007
HQ
Employees
23
Website
Sectors
Financials (LTM)
EV
$13M
Citius Pharmaceuticals Financials
Citius Pharmaceuticals reported last 12-month revenue of $45M.
In the same LTM period, Citius Pharmaceuticals generated $44M in gross profit and $3M in net income.
Revenue (LTM)
Citius Pharmaceuticals P&L
In the most recent fiscal year, Citius Pharmaceuticals reported revenue of $4M and EBITDA of ($38M).
Citius Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $45M | XXX | $4M | XXX | XXX | XXX |
| Gross Profit | $44M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 98% | XXX | — | XXX | XXX | XXX |
| EBITDA | — | XXX | ($38M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (969%) | XXX | XXX | XXX |
| EBIT Margin | 19% | XXX | (932%) | XXX | XXX | XXX |
| Net Profit | $3M | XXX | ($37M) | XXX | XXX | XXX |
| Net Margin | 7% | XXX | (949%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Citius Pharmaceuticals Stock Performance
Citius Pharmaceuticals has current market cap of $19M, and enterprise value of $13M.
Market Cap Evolution
Citius Pharmaceuticals' stock price is $0.86.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $13M | $19M | -0.7% | XXX | XXX | XXX | $-1.67 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCitius Pharmaceuticals Valuation Multiples
Citius Pharmaceuticals trades at 0.3x EV/Revenue multiple, and (0.3x) EV/EBITDA.
EV / Revenue (LTM)
Citius Pharmaceuticals Financial Valuation Multiples
As of April 18, 2026, Citius Pharmaceuticals has market cap of $19M and EV of $13M.
Equity research analysts estimate Citius Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Citius Pharmaceuticals has a P/E ratio of 6.5x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $19M | XXX | $19M | XXX | XXX | XXX |
| EV (current) | $13M | XXX | $13M | XXX | XXX | XXX |
| EV/Revenue | 0.3x | XXX | 3.4x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (0.3x) | XXX | XXX | XXX |
| EV/EBIT | 1.6x | XXX | (0.4x) | XXX | XXX | XXX |
| EV/Gross Profit | 0.3x | XXX | — | XXX | XXX | XXX |
| P/E | 6.5x | XXX | (0.5x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (0.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Citius Pharmaceuticals Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Citius Pharmaceuticals Margins & Growth Rates
Citius Pharmaceuticals' revenue in the last 12 month grew by 155%.
Citius Pharmaceuticals' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $1.7M for the same period.
Citius Pharmaceuticals Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 155% | XXX | 1885% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (969%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (7%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.7M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 32% | XXX | 745% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 18% | XXX | 232% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 977% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Citius Pharmaceuticals Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Citius Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| DexTech Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Quantum BioPharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Exact Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Biofrontera | XXX | XXX | XXX | XXX | XXX | XXX |
| VYNE Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Citius Pharmaceuticals M&A Activity
Citius Pharmaceuticals acquired XXX companies to date.
Last acquisition by Citius Pharmaceuticals was on XXXXXXXX, XXXXX. Citius Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Citius Pharmaceuticals
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCitius Pharmaceuticals Investment Activity
Citius Pharmaceuticals invested in XXX companies to date.
Citius Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Citius Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Citius Pharmaceuticals
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Citius Pharmaceuticals
| When was Citius Pharmaceuticals founded? | Citius Pharmaceuticals was founded in 2007. |
| Where is Citius Pharmaceuticals headquartered? | Citius Pharmaceuticals is headquartered in United States. |
| How many employees does Citius Pharmaceuticals have? | As of today, Citius Pharmaceuticals has over 23 employees. |
| Who is the CEO of Citius Pharmaceuticals? | Citius Pharmaceuticals' CEO is Leonard L. Mazur. |
| Is Citius Pharmaceuticals publicly listed? | Yes, Citius Pharmaceuticals is a public company listed on Nasdaq. |
| What is the stock symbol of Citius Pharmaceuticals? | Citius Pharmaceuticals trades under CTXR ticker. |
| When did Citius Pharmaceuticals go public? | Citius Pharmaceuticals went public in 2011. |
| Who are competitors of Citius Pharmaceuticals? | Citius Pharmaceuticals main competitors are DexTech Medical, Quantum BioPharma, Exact Therapeutics, Biofrontera. |
| What is the current market cap of Citius Pharmaceuticals? | Citius Pharmaceuticals' current market cap is $19M. |
| What is the current revenue of Citius Pharmaceuticals? | Citius Pharmaceuticals' last 12 months revenue is $45M. |
| What is the current revenue growth of Citius Pharmaceuticals? | Citius Pharmaceuticals revenue growth (NTM/LTM) is 155%. |
| What is the current EV/Revenue multiple of Citius Pharmaceuticals? | Current revenue multiple of Citius Pharmaceuticals is 0.3x. |
| Is Citius Pharmaceuticals profitable? | Yes, Citius Pharmaceuticals is net-income-positive (as of the last 12 months). |
| What is the current net income of Citius Pharmaceuticals? | Citius Pharmaceuticals' last 12 months net income is $3M. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.